Hubei Biocause Pharmaceutical Co Ltd
SZSE:000627
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.64
4.95
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Hubei Biocause Pharmaceutical Co Ltd
Revenue
Hubei Biocause Pharmaceutical Co Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
Hubei Biocause Pharmaceutical Co Ltd
SZSE:000627
|
Revenue
¥45.3B
|
CAGR 3-Years
7%
|
CAGR 5-Years
1%
|
CAGR 10-Years
46%
|
|
|
China Life Insurance Co Ltd
SSE:601628
|
Revenue
¥387.8B
|
CAGR 3-Years
-32%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-1%
|
|
|
Ping An Insurance Group Co of China Ltd
SSE:601318
|
Revenue
¥820.9B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
7%
|
|
|
New China Life Insurance Company Ltd
SSE:601336
|
Revenue
¥43.6B
|
CAGR 3-Years
-42%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-12%
|
|
|
S
|
Sunshine Insurance Group Co Ltd
HKEX:6963
|
Revenue
¥69.1B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Hubei Biocause Pharmaceutical Co Ltd
Glance View
Hubei Biocause Pharmaceutical Co., Ltd. is an investment holding company that engages in the insurance industry. The company is headquartered in Jingmen, Hubei and currently employs 2,239 full-time employees. is a China-based company principally engaged in insurance business, such as life insurance, health insurance and casualty insurance. The firm is also involved in pharmaceutical business and chemical business. The Company’s products include polypropylene and Ibuprofen. The firm distributes its products in domestic market and to overseas markets, with Central China and South China as its main markets.
See Also
What is Hubei Biocause Pharmaceutical Co Ltd's Revenue?
Revenue
45.3B
CNY
Based on the financial report for Jun 30, 2024, Hubei Biocause Pharmaceutical Co Ltd's Revenue amounts to 45.3B CNY.
What is Hubei Biocause Pharmaceutical Co Ltd's Revenue growth rate?
Revenue CAGR 10Y
46%
Over the last year, the Revenue growth was -18%. The average annual Revenue growth rates for Hubei Biocause Pharmaceutical Co Ltd have been 7% over the past three years , 1% over the past five years , and 46% over the past ten years .
You don't have any saved screeners yet
